Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 1/2017

Open Access 01-01-2017 | Original Article

Sclerostin does not play a major role in the pathogenesis of skeletal complications in type 2 diabetes mellitus

Authors: M. Pereira, S. Gohin, N. Lund, A. Hvid, P. J. Smitham, M. J. Oddy, I. Reichert, D. Farlay, J. P. Roux, M. E. Cleasby, C. Chenu

Published in: Osteoporosis International | Issue 1/2017

Login to get access

Abstract

Summary

In contrast to previously reported elevations in serum sclerostin levels in diabetic patients, the present study shows that the impaired bone microarchitecture and cellular turnover associated with type 2 diabetes mellitus (T2DM)-like conditions in ZDF rats are not correlated with changes in serum and bone sclerostin expression.

Introduction

T2DM is associated with impaired skeletal structure and a higher prevalence of bone fractures. Sclerostin, a negative regulator of bone formation, is elevated in serum of diabetic patients. We aimed to relate changes in bone architecture and cellular activities to sclerostin production in the Zucker diabetic fatty (ZDF) rat.

Methods

Bone density and architecture were measured by micro-CT and bone remodelling by histomorphometry in tibiae and femurs of 14-week-old male ZDF rats and lean Zucker controls (n = 6/group).

Results

ZDF rats showed lower trabecular bone mineral density and bone mass compared to controls, due to decreases in bone volume and thickness, along with impaired bone connectivity and cortical bone geometry. Bone remodelling was impaired in diabetic rats, demonstrated by decreased bone formation rate and increased percentage of tartrate-resistant acid phosphatase-positive osteoclastic surfaces. Serum sclerostin levels (ELISA) were higher in ZDF compared to lean rats at 9 weeks (+40 %, p < 0.01), but this difference disappeared as their glucose control deteriorated and by week 14, ZDF rats had lower sclerostin levels than control rats (−44 %, p < 0.0001). Bone sclerostin mRNA (qPCR) and protein (immunohistochemistry) were similar in ZDF, and lean rats at 14 weeks and genotype did not affect the number of empty osteocytic lacunae in cortical and trabecular bone.

Conclusion

T2DM results in impaired skeletal architecture through altered remodelling pathways, but despite altered serum levels, it does not appear that sclerostin contributes to the deleterious effect of T2DM in rat bone.
Literature
1.
Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T (2009) Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res Off J Am Soc Bone Miner Res 24:702–709CrossRef
2.
Loder RT (1988) The influence of diabetes mellitus on the healing of closed fractures. Clinical orthopaedics and related research 210–216
3.
Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 18:427–444CrossRef
4.
Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N (1996) Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res Off J Am Soc Bone Miner Res 11:931–937CrossRef
5.
Lecka-Czernik B (2008) Local and systemic functions of bone fat and its contribution to the energy metabolism—the effect of diabetes and obesity on bone. J Musculoskelet Nueronal Interact 8:346–347
6.
Clemens TL, Karsenty G (2011) The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res Off J Am Soc Bone Miner Res 26:677–680CrossRef
7.
Li X, Ominsky MS, Niu QT, et al. (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res Off J Am Soc Bone Miner Res 23:860–869CrossRef
8.
Hie M, Iitsuka N, Otsuka T, Tsukamoto I (2011) Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation. Int J Mol Med 28:455–462PubMed
9.
Portal-Nunez S, Lozano D, de Castro LF, de Gortazar AR, Nogues X, Esbrit P (2010) Alterations of the Wnt/beta-catenin pathway and its target genes for the N- and C-terminal domains of parathyroid hormone-related protein in bone from diabetic mice. FEBS Lett 584:3095–3100CrossRefPubMed
10.
Gennari L, Merlotti D, Valenti R, et al. (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97:1737–1744CrossRefPubMed
11.
Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-Salcedo JA, Munoz-Torres M (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97:234–241CrossRefPubMed
12.
Kim JY, Lee SK, Jo KJ, Song DY, Lim DM, Park KY, Bonewald LF, Kim BJ (2013) Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes. Life Sci 92:533–540CrossRefPubMed
13.
Hamann C, Rauner M, Hohna Y, et al. (2013) Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res Off J Am Soc Bone Miner Res 28:627–638CrossRef
14.
Balint E, Szabo P, Marshall CF, Sprague SM (2001) Glucose-induced inhibition of in vitro bone mineralization. Bone 28:21–28CrossRefPubMed
15.
Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T (2015) Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun 461:193–199CrossRefPubMed
16.
Yokoi N, Hoshino M, Hidaka S, Yoshida E, Beppu M, Hoshikawa R, Sudo K, Kawada A, Takagi S, Seino S (2013) A novel rat model of type 2 diabetes: the Zucker fatty diabetes mellitus ZFDM rat. J Diabetes Res 2013:103731CrossRefPubMedPubMedCentral
17.
Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305–317CrossRefPubMed
18.
Tamasi JA, Arey BJ, Bertolini DR, Feyen JH (2003) Characterization of bone structure in leptin receptor-deficient Zucker (fa/fa) rats. J Bone Miner Res Off J Am Soc Bone Miner Res 18:1605–1611CrossRef
19.
20.
Hamann C, Goettsch C, Mettelsiefen J, et al. (2011) Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Phys Endocrinol Metab 301:E1220–E1228CrossRef
21.
Reinwald S, Peterson RG, Allen MR, Burr DB (2009) Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. Am J Phys Endocrinol Metab 296:E765–E774CrossRef
22.
Liu Z, Aronson J, Wahl EC, Liu L, Perrien DS, Kern PA, Fowlkes JL, Thrailkill KM, Bunn RC, Cockrell GE, Skinner RA, Lumpkin CK, Jr. (2007) A novel rat model for the study of deficits in bone formation in type-2 diabetes. Acta Orthop 78(1):46–55
23.
Prisby RD, Swift JM, Bloomfield SA, Hogan HA, Delp MD (2008) Altered bone mass, geometry and mechanical properties during the development and progression of type 2 diabetes in the Zucker diabetic fatty rat. J Endocrinol 199:379–388CrossRefPubMed
24.
Woo SM, Rosser J, Dusevich V, Kalajzic I, Bonewald LF (2011) Cell line IDG-SW3 replicates osteoblast-to-late-osteocyte differentiation in vitro and accelerates bone formation in vivo. J Bone Miner Res Off J Am Soc Bone Miner Res 26:2634–2646CrossRef
25.
Feagin F, Koulourides T, Pigman W (1969) The characterization of enamel surface demineralization, remineralization, and associated hardness changes in human and bovine material. Arch Oral Biol 14:1407–1417CrossRefPubMed
26.
Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T (2009) Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 32:2263–2268CrossRefPubMedPubMedCentral
27.
Picke AK, Gordaliza Alaguero I, Campbell GM, Gluer CC, Salbach-Hirsch J, Rauner M, Hofbauer LC, Hofbauer C (2015) Bone defect regeneration and cortical bone parameters of type 2 diabetic rats are improved by insulin therapy. Bone
28.
Liu R, Bal HS, Desta T, Krothapalli N, Alyassi M, Luan Q, Graves DT (2006) Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. J Dent Res 85(6):510–514CrossRefPubMedPubMedCentral
29.
Mansur SA, Mieczkowska A, Flatt PR, Bouvard B, Chappard D, Irwin N, Mabilleau G (2016) A new stable GIP-Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus. Bone 87:102–113CrossRefPubMed
30.
Glorie L, Behets GJ, Baerts L, De Meester I, D’Haese PC, Verhulst A (2014) DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J Phys Endocrinol Metab 307:E447–E455CrossRef
31.
Hamada Y, Fujii H, Fukagawa M (2009) Role of oxidative stress in diabetic bone disorder. Bone 45(Suppl 1):S35–S38CrossRefPubMed
32.
Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T (2007) The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Hormone and metabolic research = Hormon- und Stoffwechselforschung =. Horm Metab 39:871–875CrossRef
33.
Campbell GM, Tiwari S, Hofbauer C, et al. (2016) Effects of parathyroid hormone on cortical porosity, non-enzymatic glycation and bone tissue mechanics in rats with type 2 diabetes mellitus. Bone 82:116–121CrossRefPubMed
34.
Zhou Z, Immel D, Xi CX, Bierhaus A, Feng X, Mei L, Nawroth P, Stern DM, Xiong WC (2006) Regulation of osteoclast function and bone mass by RAGE. J Exp Med 203:1067–1080CrossRefPubMedPubMedCentral
35.
Kang J, Boonanantanasarn K, Baek K, Woo KM, Ryoo HM, Baek JH, Kim GS (2015) Hyperglycemia increases the expression levels of sclerostin in a reactive oxygen species- and tumor necrosis factor-alpha-dependent manner. J Periodontal Implant Sci 45:101–110CrossRefPubMedPubMedCentral
36.
Garcia-Hernandez A, Arzate H, Gil-Chavarria I, Rojo R, Moreno-Fierros L (2012) High glucose concentrations alter the biomineralization process in human osteoblastic cells. Bone 50:276–288CrossRefPubMed
37.
You L, Gu W, Chen L, Pan L, Chen J, Peng Y (2014) MiR-378 overexpression attenuates high glucose-suppressed osteogenic differentiation through targeting CASP3 and activating PI3K/Akt signaling pathway. Int J Clin Exp Pathol 7:7249–7261PubMedPubMedCentral
38.
Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ 3rd, Khosla S (2011) Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res Off J Am Soc Bone Miner Res 26:373–379CrossRef
39.
Thompson ML, Jimenez-Andrade JM, Mantyh PW (2016) Sclerostin Immunoreactivity increases in cortical bone osteocytes and decreases in articular cartilage chondrocytes in aging mice. J Histochem Cytochem : Off J Histochem Soc 64:179–189CrossRef
40.
Jastrzebski S, Kalinowski J, Stolina M, Mirza F, Torreggiani E, Kalajzic I, Won HY, Lee SK, Lorenzo J (2013) Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. J Bone Miner Res Off J Am Soc Bone Miner Res 28:618–626CrossRef
41.
Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, Drake MT, Monroe DG, Khosla S (2014) Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59:1–6CrossRefPubMed
42.
43.
Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY (2009) Inhibition of osteoblastic bone formation by nuclear factor-nB. Nat Med 15:682–689CrossRefPubMedPubMedCentral
44.
45.
Skurk T, Alberti-Huber C, Herder C, Hauner H (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92:1023–1033CrossRefPubMed
Metadata
Title
Sclerostin does not play a major role in the pathogenesis of skeletal complications in type 2 diabetes mellitus
Authors
M. Pereira
S. Gohin
N. Lund
A. Hvid
P. J. Smitham
M. J. Oddy
I. Reichert
D. Farlay
J. P. Roux
M. E. Cleasby
C. Chenu
Publication date
01-01-2017
Publisher
Springer London
Published in
Osteoporosis International / Issue 1/2017
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3718-0

Other articles of this Issue 1/2017

Osteoporosis International 1/2017 Go to the issue

Original Article

Fracture risk in people with developmental disabilities: results of a large claims data analysis

Original Article

Understanding fragility fracture patients’ decision-making process regarding bisphosphonate treatment

Original Article

Three doses of vitamin D, bone mineral density, and geometry in older women during modest weight control in a 1-year randomized controlled trial

Review

Impact of vitamin D replacement in adults and elderly in the Middle East and North Africa: a systematic review and meta-analysis of randomized controlled trials

Original Article

Effect of high-dose cholecalciferol (vitamin D3) on bone and body composition in children and young adults with HIV infection: a randomized, double-blind, placebo-controlled trial

Erratum

Erratum to: Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the osteoporotic fractures in men (MrOS) study